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dendritic cells with different chemoattractive 
properties
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Abstract 
Background: Dendritic cells (DC) are currently implemented as immunotherapeutic strategy for the treatment of 
tumor patients based on their central role in the immune system. Despite good results were obtained in vitro and in 
animal models, their clinical use has provided limited success suggesting the requirement to optimise the protocol for 
their production.
Methods: A cDNA array was performed on FastDC obtained from the differentiation of human peripheral blood 
monocytes stimulated with the clinical gold standard or with two alternative maturation cocktails combining inter-
feron (IFN)γ and ligands for different toll like receptors (TLR).
Results: A stronger modulation of the DC transcriptome with respect to immature DC was found in alternatively 
stimulated DC when compared to DC stimulated with the clinical gold standard. A major class of molecules differen-
tially expressed using distinct DC stimulation protocols were chemokines. Validation of their differential expression 
pattern at the mRNA and protein level confirmed the secretion of inflammatory chemokines by the alternative DC. 
Functional analyses of the chemotactic properties of DC “wash out” supernatants highlighted the ability of alternative, 
but not of gold standard DC to efficiently recruit immune cells with a prevalence of monocytes. Effector cells belong-
ing to the innate as well as adaptive immunity were also attracted and the interaction with alternative DC resulted in 
enhanced secretion of IFNγ and induction of cytotoxic activity. Using leukocytes from cancer patients, it was demon-
strated that the monocyte-attracting activity targeted cells with an inflammatory phenotype characterised by high 
levels of HLA-DR expression.
Conclusions: Despite other classes of immune modulatory genes differently expressed in the alternative DC require 
to be investigated and characterised regarding their functional consequences, the reduced maturation state and 
chemoattractive properties of the gold standard versus alternative DC clearly promote the necessity to change the 
clinically used maturation cocktail of DC in order to improve the outcome of patients treated with DC-based vaccines.
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Background
During the last two decades strategies have been devel-
oped to implement dendritic cell (DC)-based therapies 
for the treatment of cancer. Despite their successful 
usage in murine models, this approach demonstrated 
only a limited efficacy in the human setting, although 
the approval of sipuleucel-T (also called APC8015 or 
Provenge®) [1] from the Food and Drug Administration 
for the therapy of prostate cancer patients has provided 
new strength to further pursuing this path.
In order to improve the functionality of vaccine DC the 
established protocols have been modified by changing (1) 
the source of cells [2, 3], (2) the differentiation protocol 
when starting from monocytes or precursor cells [4–6] 
and (3) the composition of the maturation cocktails in 
order to provide all necessary functions to the DC [7–9].
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In addition to providing all the required signals for a 
proper activation of effector cells, an important require-
ment of vaccine DC is their ability to “reach” the effec-
tor cells, mediated either by their own migration or by 
the recruitment of effector cells. Chemokines and their 
receptors exploit a central role in the correct homing of 
immune cells under homeostatic and inflammatory con-
ditions [10]. Whereas the ability of vaccine DC to migrate 
toward secondary lymphoid organs has been deeply 
investigated, less attention has been paid to their chem-
oattracting properties.
Recently, we demonstrated that monocytes differenti-
ated with the shortened 48 h-long Fast protocol [5] and 
stimulated with alternative (alt-) cocktails containing toll 
like receptor (TLR) ligands and interferon (IFN)γ (for full 
description see Table  1) displayed an enhanced ability 
to interact with innate and adaptive effector cells when 
compared to the gold standard cytokine cocktail-matured 
DC due to an enhanced expression of costimulatory 
molecules and secretion of interleukin (IL-)12p70 (see 
Table 2; Ref. [11]). In order to further dissect the differ-
ences of DC matured with the gold standard or the alter-
native cocktails, cDNA microarrays were performed. As 
expected, an enhanced number of differentially expressed 
genes could be detected in alternative versus gold stand-
ard DC, with many genes belonging to immunologically 
relevant pathways. Interestingly, the secretion of a num-
ber of pro-inflammatory chemokines was enhanced in 
alternatively matured DC. Consequently they displayed 
an enhanced ability to recruit other immune cells to the 
vaccine DC proximity. Alterations in the set of expressed 
chemokines might be important for the choice of DC 
for the treatment of tumors known to be susceptible 




Monophosphoryl lipid A (MPLA) and the imidazoqui-
noline compound CL097 were purchased from Invivo-
Gen, IL1β from Biosource, IFNα2b from ProSpec, IFNγ 
from Immunotools, tumor necrosis factor (TNF)α from 
Peprotech, polyinosinic:polycytidylic acid (polyIC) and 
prostaglandin (PG)E2 from Sigma-Aldrich, whereas IL6 
was a kind gift from S. Rose-John (Institute of Biochemis-
try, University of Kiel, Kiel, Germany).
Following monoclonal antibodies (mAb) were used: PE 
anti-HLA-DR, Alexa Fluor®700 anti-CD3, eFluorTM450 
anti-CD16, PE-Cy7 anti-CD14, allophycocyanin-
efluor780 anti-CD4 (eBioscience/Affimetrix GmbH), 
PE-Cy7 anti-CD56 (Beckman Coulter), FITC anti-Vδ2 
TCR, allophycocynin anti-CD107a, BV570 anti-CD8α 
(Biolegend Inc.), allophycocyanin anti-CD14, allophyco-
cyanin anti-CD25, PE anti-CD127, PE-Cy7 anti-CD33, 
FITC anti-CD11b (Becton–Dickinson) and PE anti-
CCR7 (R&D System).
DC purification, differentiation and maturation
Buffy coats from healthy donors were obtained from the 
blood bank, whereas samples from melanoma and renal 
cell carcinoma (RCC) patients were obtained from the 
Clinic of Dermatology (Wolfgang Marsch) and the Clinic 
of Urology (Paolo Fornara) of the University Hospital 
Kroellwitz of the Martin Luther University Halle-Witten-
berg in Halle (Saale). Samples were provided upon writ-
ten informed consent and the procedure was approved 
by the University ethic committee. Overall, blood sam-
ples of more than 20 different healthy donors as well as 
4 melanoma and 3 RCC patients were employed in the 
different experiments.
Table 1 Characteristics of the DC maturation cocktails
Name Components Concentrations









Alt-1 TNFα + IL1β + IFNα + IFNγ + pIC
Alt-2 IFNγ + MPLA
Alt-3 TNFα + IL1β + IFNγ + CL097
Table 2 Summary of fast DC characteristics
a x-fold in MFI to immature DC; mean ± SE of >10 donors.
b pg/mL secreted during the 18 h maturation period; mean ± SE of >10 donors.
c pg/mL secreted by mature DC re-seeded at 106 cell/mL for 24 h; mean ± SE of 
>7 donors.
Molecule Gold st DC Alt-1 DC Alt-2 DC Alt-3 DC
CD40a 3.7 ± 0.2 10.6 ± 0.8 10.6 ± 0.7 8.1 ± 0.6
CD54a 3.6 ± 0.1 6.2 ± 0.3 6.9 ± 0.2 3.8 ± 0.2
CD80a 2 ± 0.1 4.4 ± 0.2 4.2 ± 0.3 3.5 ± 0.2
CD83a 5.8 ± 0.4 4.7 ± 0.4 7.7 ± 0.5 3.0 ± 0.2
CD86a 8.6 ± 0.7 8.8 ± 1.0 13.4 ± 1.1 4.2 ± 0.3
IL12b 35 ± 15 8,908 ± 1,466 7,283 ± 1,378 2,804 ± 483
IL12c 31 ± 9 828 ± 175 583 ± 215 47 ± 10
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Peripheral blood mononuclear cells (PBMC) were 
obtained by gradient centrifugation on a Pancoll gradient 
(Pan-biotech) using Leucosep tubes (Greiner bio-one). 
The isolated cells were either frozen in 90% FBS (Life 
technologies) and 10% DMSO (Carl Roth GmbH) until 
their use for functional analysis or directly subjected to 
magnetic purification of CD14+ monocytes by mean of 
CD14-conjugated beads (Miltenyi biotec) following man-
ufacturers’ instructions.
Monocytes were differentiated as previously described 
[11]. Briefly, 106 monocytes/mL were differentiated in 
CellGro medium (CellGenix) with 200  ng/mL granulo-
cyte macrophage colony-stimulating factor (GM-CSF; 
Leukine; Bayer HealthCare) and 1,000 U/mL IL4 (Immu-
notools,) for 24–36 h and then stimulated for 18 h with 
the following maturation cocktails (see also Table  1): 
(1) gold standard (TNFα  +  IL1β  +  IL6  +  PGE2); (2) 
alternative (alt-)1, or alpha-type1 polarising (TNFα  + 
IL1β + IFNα + IFNγ + polyIC); (3) alt-2 (IFNγ + MPLA) 
and (4) alt-3 (TNFα +  IL1β +  IFNγ +  CL097). Mature 
DC were evaluated for phenotype by flow cytometry as 
previously described [11] and then subjected to mRNA 
extraction or re-seeded in the absence of further stimuli 
to evaluate the fate of “wash out” cells. After 24  h, the 
“wash out” supernatants were collected and kept frozen 
at −20°C until further use while the cells were lysed with 
Trizol reagent (Invitrogen) for mRNA extraction.
cDNA array evaluation of mature DC
The gene expression patterns of immature DC and DC 
stimulated with gold standard, alt-1 and alt-2 cocktails 
were compared at the transcriptomic level using the 
Hs-CCDTM36k oligo array printed at Immunogenet-
ics lab, Department of Transfusion Medicine, Clinical 
Center, National Institutes of Health. Briefly, 106 cells 
were lysed in Trizol reagent (Invitrogen) and RNA was 
isolated following manufacturers’ instructions. 3  µg of 
total RNA/sample was amplified as previously described 
[12]. RNA obtained by pooling PBMCs from six normal 
donors served as a reference and was amplified as the 
test samples. aRNAs were directly labeled using ULS 
aRNA Fluorescent Labeling kit (Kreatech) with Cy3 for 
reference and Cy5 for test samples and co-hybridized to 
a 36k whole transcriptome human oligo array for 18  h 
at 45°C before the arrays were washed and scanned by 
Agilent Scanner (Agilent Biotechnology) [13]. The data 
were uploaded to the mAdb database at http://nciarray.
nci.nih.gov and further analyzed using BRBArray-Tools 
developed by the Biometric Research Branch, National 
Cancer Institute (http://linus.nci.nih.gov/BRB-Array-
Tools.html) [14]. Class comparison was performed using 
F test to identify differentially expressed genes among 
experimental groups and differentially expressed genes 
were defined as p value <0.005.
Quantification of chemokines at mRNA and protein level
For validation of the array data quantitative real time 
PCR (qPCR) was performed. Briefly, 1–2 μg RNA were 
retro-transcribed into cDNA using RevertAid H minus 
first strand cDNA synthesis kit (Fisher Scientific) fol-
lowed by amplification of target genes using the platinum 
Sybr Green qPCR Supermix (Invitrogen) and a Rotor-
Gene6000 machine (Qiagen). The qPCR reaction con-
sisted of 5 min denaturation at 95°C, followed by 40 cycle 
of 10 s at 72°C and 30 s at 62°C. Melting curve analysis of 
the qPCR reactions were used to evaluate the specificity 
of amplification. The transcription was quantified using 
the ΔCt method and data were normalized to GAPDH 
and HPRT1 as house-keeping genes. Following primers 
were used: GAPDH (GAGAAGGCTGGGGCTCATT 
TGC, GGACTGTGGTCATGAGTCCTTCC), HPRT1 
(GCTGGATTACATCAAAGCACTG, CTGACCAAGG 
AAAGCAAAGTCT), CCL2 (CCCCAGTCACCTGCTG 
TTAT, TGGAATCCTGAACCCACTTC), CCL3L (CTCT 
GCAACCAGGTCCTCTC, TTTCTGGACCCACTCCT 
CAC: amplify CCL3L1 and CCL3L3, but not CCL3), C 
CL4 (TACCATGAAGCTCTGCGTGA, TACCACAAAG 
TTGCGAGGAA; amplify CCL4, CLL4L1 and CCL 
4L2), CCL5 (CGCTGTCATCCTCATTGCTA, ACACAC 
TTGGCGGTTCTTTC), CCL8 (CCCTCCAAGATGAAG 
GTTTC, GAATCCCTGACCCATCTCTC), CCL13 (TGC 
ACTCAACGTCCCATCTA, ACTTCTCCTTTGGGTCA 
GCA), CCL17 (TTCAAAACCAGGGTGTCTCC, CTGC 
CCTGCACAGTTACAAA), CCL22 (ACTGCACTC 
CTGGTTGTCCT, GCTCTTCATTGGCTCAGCTT), 
CCL23 (TTTGAAACGAACAGCGAGTG, TGTGTCCC 
TTCACCTTGACA), CXCL8 (TTGCCAAGGAGTGCT 
AAAGAA, CAGACAGAGCTCTCTTCCATCA), CXCL9 
(TGCTGGTTCTGATTGGAGTG, TTTGGCTGACCTG 
TTTCTCC), CXCL10 (CAACACGTGGACAAAATT 
GG, TCCAGTCTCAGCACCATGAA), CXCL11 (AGAG 
GACGCTGTCTTTGCAT, TAAGCCTTGCTTGCTTC 
GAT), CXCL16 (CTCCTGGCCATCATCTTCAT, AAGC 
TTCCATTCTTGGCTCA),
The chemokine concentrations in the DC “wash out” 
supernatants were determined by sandwich ELISA for 
CCL2, CCL3, CCL5, CCL8, CXCL9 and CXCL16 (all 
from PeproTech) and by flow cytometric plexing for 
CCL4/MIP-1β, CXCL8/IL8 and CXCL10/IP-10 (CBA 
multiplexing kit, Becton–Dickinson). Expression of 
transmembrane CXCL16 on mature DC was evaluated 
by flow cytometry using a biotinylated anti-CXCL16 Ab 
(PeproTech) followed by streptavidin PE (eBioscience/
Affimetrix).
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DC migration assay
Mature DC (2 × 104) were seeded in 200 μL medium 
in a 4 μm thincert insert well (Greiner bio-one), while 
in the lower chamber of the 24 well plate  600  μL 
medium containing 100  ng/mL of CCL21 (Pepto-
tech) were added. After 3  h incubation at 37°C, cells 
migrated into the lower compartment were collected. 
Samples were analysed on a Navios (Beckman Coul-
ter) flow cytometer under constant flow for 2  min 
after addition of propidium iodide in order to dis-
criminate dead cells. Counting beads (Beckman Coul-
ter) were also added to the samples directly before 
measurement in order to normalise acquisition rates 
among the samples.
PBMC migration assay
Cryopreserved total PBMC from healthy donors and 
cancer patients were thawed and 1.5  ×  106 cells were 
seeded in 300 μL medium in a 3 μm Thincert insert well 
(Greiner bio-one). In the bottom chamber of the 12 well 
plate 1 mL of medium or different dilutions (1:2 to 1:3) of 
the “wash out” supernatants from the different DC were 
added as chemoattractant. After 3  h incubation at 37°C, 
cells from the bottom chamber were collected and stained 
with fluorochrome-labelled antibodies in order to iden-
tify the different immune populations, namely monocytes 
(as CD14+, SSChigh), CD4+ and CD8+ T cells (as CD3+ 
and CD4+ or CD8+, respectively), γδ T cells (as CD3+ 
Vδ2 TCR+) and the two natural killer (NK) subpopula-
tions of CD56br and CD16+ cells (as CD3neg and CD56br/
CD16neg and CD56dim/CD16+, respectively). PBMC from 
cancer patients were also evaluated for the phenotype of 
monocytes by evaluating expression of CD33, CD11b and 
HLA-DR and for the presence of regulatory T cells (Treg) 
as CD25high CD127low CD4+ T cells. Examples of gating 
strategy are given in Figures 1c and 2c.
Samples were measured on a Navios (Beckman Coul-
ter) flow cytometer under constant flow for 2  min after 
addition of propidium iodide in order to discriminate 
dead cells. Counting beads (Beckman Coulter) were also 
added to the samples directly before acquisition to fur-
ther normalise acquisition rates among samples.
Functional evaluation of migrated cells
Mature DC (5 × 105) were seeded in 1 mL in the lower 
chamber of a 12 well plate. After 4  h preincubation 
2.5–3 ×  106 thawed autologous PBMC were added in a 
3 μm Thincert insert well and allowed to migrate. After 
18  h the migrated cells were collected and functionally 
evaluated as previously described [11]. Briefly, the ability 
to secrete IFNγ was determined using a secretion assay 
kit (Milteny biotech) according to the manufacturer’s 
instruction, whereas their cytotoxic activity was analysed 
employing the CD107a degranulation assay after 4  h 
incubation with 105 Daudi cells. For evaluation of T cell 
functionality the mature DC were pulsed with 1  μg of 
SEB for 30 min at 37°C. After washing and 4 h pre-incu-
bation for chemokine secretion, PBMC were added and 
allowed to migrate for 3–4 h before undergoing the IFNγ 
secretion assay.
Statistical analysis
Differences between treatments were evaluated using 
the one-way ANOVA test for correlated samples and the 
Tukey post hoc test. Values of p < 0.05 were considered 
significant.
Results
Increased alteration of the DC transcriptome  
using alternative maturation cocktails
We previously characterized the phenotype and func-
tional activity of monocytes differentiated into DC 
using the shortened “FastDC” protocol and stimu-
lated with the clinical gold standard cytokine cocktail 
or with alternative cocktails based on a combination 
of different TLR  ligands with IFNγ (for detailed com-
position see Table  1). Now, a transcriptome-wide 
comparison was performed by cDNA array using 
immature, gold standard and the alt-1 and alt-2 cock-
tails, previously demonstrated to have the highest 
functional interaction with effector cells [11]. Com-
parison of immature DC with DC stimulated with the 
three cocktails resulted in a significant altered expres-
sion pattern with 483 differentially expressed genes 
reaching statistical significance by F test (p  <  0.005; 
Figure  3a). Among them, 78 genes were up-regulated 
(highlighted as box I in Figure  3a) and 86 down-reg-
ulated (box II in Figure  3a) in all three mature DC 
versus immature DC, whereas the two alternatively 
matured DC had additional 172 genes up-regulated 
and 80 down-regulated genes when compared to 
both immature and gold standard DC (Figure  3a, box 
III and IV, respectively). Evaluation of the classes 
and canonical pathways of differentially expressed 
genes highlighted the highest significance in changes 
of genes involved in the cross-talk of DC and innate 
cells, in T helper differentiation and in IFN signalling 
(Figure  3b). Further comparison between alt-1 and 
alt-2 DC revealed 244 significantly differentially 
expressed gene with 181 up-regulated in the alt-1 and 
63 in the alt-2 DC (Figure 3c). Analysis of the canoni-
cal pathway demonstrated a reduced expression of 
genes associated with cell death and an enhanced 
expression of pathways associated with cell movement, 
immune cell trafficking and inflammation response in 
alt-2 DC versus alt-1 DC (data not shown).
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Figure 1 Enhanced migration of healthy donor PBMC toward conditioned supernatants from alternative DC. “Wash out” supernatants collected 
24 h after seeding mature DC in the absence of exogenous stimuli were used as a source of chemoattractants for immune cells. Total PBMC from 
healthy donors were loaded in a trans-well insert (3 μm pores) and allowed to migrate toward medium or DC “wash out” supernatants for 3 h. 
Migrated cells were analysed by flow cytometry to determine their total number (a) as well as their distribution into the different immune cell 
subpopulations (b) by using the indicated gating strategy (c). Data from seven different experiments are reported as mean ± SE after normalization 
to supernatants from gold standard DC. *p < 0.05 in the Tukey post hoc test.
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Influence of maturation cocktails on the chemokine 
expression in DC
A high number of genes identified as differentially 
expressed in the various DC belong to the chemokine 
family. Since chemokines are known to play a key role 
in the induction of immune responses and homing of 
immune effector cells, the validation of the array data 
was focused on these molecules. Two expression patterns 
could be distinguished among the differently matured 
DC from the array data: CCL17, CCL22 and CXCL16 
were predominantly up-regulated in gold standard DC, 
while the two alternative DC had an enhanced expres-
sion of CCL3-like3 (CCL3L3), CCL4-like1 (CCL4L1) and 
CCL4L2, CCL5, CXCL8, CXCL9 and CXCL11 (Table 3).
Validation of the gene expression pattern of gold stand-
ard, alt-1 and alt-2 DC was performed by quantitative 
real time PCR (qPCR) using healthy donor preparations 
and confirmed for all chemokines the altered expres-
sion pattern highlighted by the mRNA array data 
(Figure  4). The qPCR analysis of these chemokines was 
also expanded to DC stimulated with a third alternative 
cocktail that was not included in the array evaluation due 
to its slightly lower functionality [11]. The alt-3 DC dem-
onstrated lower expression levels of CCL3, CCL4, CCL5 
as well as of CXCL11 when compared to alt-1 and alt-2 
DC (Figure 4). Furthermore, the expression of CXCL10, 
representing in addition to CXCL9 and CXCL11 a ligand 
of CXCR3, was highly up-regulated in alt-1 and alt-2 DC, 
but slightly less and statistically not significant in alt-3 
DC (Figure 4).
The differential expression pattern of selected 
chemokines was also validated at the protein level using 
supernatants obtained by re-seeding the mature DC in 
the absence of further stimuli (“wash out” supernatant) 
Figure 2 Effects of DC conditioned supernatants on PBMC from cancer patients. Total PBMC from melanoma or RCC patients were added into 
trans-well insert (3 μm pores) and allowed to migrate toward DC “wash out” supernatants for 5 h. Migrated cells were evaluated by flow cytometry 
to determine absolute number and immune composition. a Mean ± SE of the x-fold increase in the migration of the different immune populations 
over gold standard DC-derived supernatants from 4 to 6 different experiments is shown. b x-fold increase in the HLA-DR MFI of migrated CD14+ 
monocytes versus the original population. c Gating strategy (insert) and percentage of CD25high CD127low Treg of the original PBMC and among 
migrated cells shown as percentage of CD4+ T cells or of total leukocytes. *p < 0.05 in the Tukey post hoc test.
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for 24  h, a situation mimicking the secretion after in 
vivo injection. In line with the mRNA data, gold stand-
ard DC secreted marginal amounts of CCL3, CCL4, 
CCL5, CXCL9 and CXCL10 in contrast to alt-1 and 
alt-2 DC. Alt-3 DC shared high levels of CXCL9 secre-
tion with alt-1 and alt-2 DC, but did not secrete CCL5 
and produced much lower levels of CXCL10, CCL3 and 
CCL4. CXCL8 was secreted by all mature DC, but always 
at higher levels in the alternatively matured DC. Despite 
the differences at the mRNA level CXCL16 was present 
at comparable levels in the supernatants of the different 
DC (Figure 5a). Since CXCL16 is also a transmembrane 
molecule flow cytometry was performed on mature DC 
demonstrating a surface staining for CXCL16 on gold 
standard, but not on alternative DC (Figure 5b).
Long lasting production of chemokines
In order to further characterise the chemokine secreting 
capabilities of the different DC upon in vivo application, 
transcriptional profile of the wash out DC was evaluated 
by qPCR. Even 24 h after maturation, the alternative DC 
were still transcribing higher levels of CCL3L, CCL4L, 
CCL5, CXCL8, CXCL9, CXCL10 and CXCL11 in com-
parison to the gold standard DC (Figure 6). CCL17 and 
CCL22, that were prevalently expressed in the mature 
gold standard DC, displayed a more heterogeneous 
Figure 3 Effect of different maturation cocktails on DC transcriptome. Immature DC were compared to cells stimulated with gold standard, alt-1 
and alt-2 maturation cocktails using cDNA array. Three different donors were used for the evaluation. The heat map of genes differentially regulated 
among the four DC types (a) or just the two alternative DC (c) are shown. b Distribution of the differentially expressed genes in the canonical path-
ways is shown for each mature DC (gold standard DC, top; alt-1 DC, middle; alt-2 DC, bottom) versus the immature DC. The numbers above the bars 
indicate the number of genes belonging to the different pathways, whereas the yellow line indicates the -Log10 of the p value of the modulation for 
each family.
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expression among the different donors in the wash out 
DC, resulting in no statistically significant difference 
among the various maturation cocktails.
Chemokine receptor expression by the differently matured 
DC
In addition to the various chemokine genes, one 
chemokine receptor, namely CCR7 was also found to be 
significantly upregulated in all mature DC (Table 3). Flow 
cytometric analysis confirmed the enhanced expres-
sion of this receptor on all mature DC, with the high-
est expression levels in alt-1 and alt-3 DC (Figure 7a). In 
contrast, functional analysis of the receptor determined 
by a migration assay toward CCL21 demonstrated that 
gold standard DC possess a higher migratory capacity 
(Figure  7b). These data confirm previously published 
results describing a missing correlation between CCR7 
expression levels and functionality [15–17].
Chemoattractive properties of “wash out” DC supernatants
The functional relevance of the chemokine secretion by 
the various DC was then evaluated in a classical trans-
well migration assay using total PBMC from healthy 
donors and the “wash out” supernatants. After 3 h incu-
bation, only few cells had actively migrated towards the 
gold standard DC. In contrast, the supernatants from the 
alternatively matured DC attracted a 5- to 25-fold higher 
number of immune cells (Figure 1a).
Immunophenotyping of the migrated cells revealed 
that most of the cells migrating toward the alternative DC 
supernatants were CD14+ monocytes, with alt-3 DC pro-
viding the highest and alt-2 DC the lowest rate of migra-
tion among the alternative DC. In addition effector cells 
from the innate and adaptive immunity were attracted 
by the alternative DC, but to a much lower extent than 
monocytes (Figure 1b).
Evaluation of monocyte attracting chemokines
Due to the increased attraction of monocytes by alt-3 DC 
that were not present in the array evaluation, the tran-
scription of chemokines involved in monocyte attraction 
(i.e. CCL2, CCL8, CCL13 and CCL23) was determined 
in the various DC by qPCR. Among the genes analysed, 
only CCL2 was specifically up-regulated in alt-3 DC, 
with a more than 100- or 10-fold increase in transcrip-
tion when compared to immature and gold standard or 
alternative DC, respectively. CCL8 was also up-regulated 
in alt-3 DC, but the expression was shared by alt-1 DC 
(Figure  8a). These data were further confirmed at the 
protein level in “wash out” supernatants (Figure 8b).
Functionality of migrated effector cells
To evaluate the functional consequences of the attrac-
tion of effector cells, the migration experiments were 
performed using slightly changed conditions. Instead 
of “wash out” supernatants, mature DC were seeded in 
the bottom chamber and pre-cultured for 4 h in order to 
enrich the culture medium with secreted chemokines. 
Moreover, to obtain enough number of innate cells for 
functional evaluation the migration assay was prolonged 
to 18 h. Finally, for the determination of antigen-specific 
T cell activation the mature DC were pulsed with the 
model antigen staphylococcal enterotoxin B (SEB) before 
seeding.
In line with the results obtained upon co-culture condi-
tions [11] only γδ T cells and NK cells that had migrated 
to alt-1 or alt-2 DC were able to secrete IFNγ, whereas no 
secretion was obtained in response to gold standard or 
Table 3 cDNA array data of chemokine and chemokine receptor genes
a DC code for statistical comparison.
b Value not available.
Array rank Gene Univariate F test  
p value
Geometric mean of ratios Pairwise significant  
(p < 0.01)a
Imm (#1)a Gold st (#2)a Alt-1 (#3)a Alt-2 (#4)a
2 CCL5 1.00E−007 0.04 0.06 3.18 2.53 (1.3) (1.4) (2.3) (2.4)
16 CCL17 2.90E−006 2.29 63.78 31.39 47.56 (1.2) (1.3) (1.4)
18 CCL4L1 3.40E−006 0.46 0.57 3.47 2.44 (1.3) (1.4) (2.3) (2.4)
28 CCL4L2 7.10E−006 1 1.07 11.43 7.7 (1.3) (1.4) (2.3) (2.4)
167 CXCL8 4.98E−004 0.02 0.1 0.44 0.32 (1.2) (1.3) (1.4) (2.3)
195 CCL3L3 7.85E−004 6.58 1.9 6.61 3.79 (2.1) (2.3) (2.4)
247 CCR7 1.32E−003 0.85 4.74 12.02 8.41 (1.2) (1.3) (1.4)
257 CXCL11 1.41E−003 0.4 0.4 1.15 2.63 (1.4) (2.4)
391 CXCL9 3.03E−003 0.55 0.44 8.75 10.61 (1.3) (1.4) (2.3) (2.4)
411 CCL22 3.44E−003 NAb 47.6 11.42 31.93
458 CXCL16 4.35E−003 0.79 1.79 1.01 0.93 (1.2) (3.2) (4.2)
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alt-3 DC (Figure  9a). Regarding the acquisition of cyto-
toxic activity, all innate effector types displayed a basal 
level of CD107a degranulation in response to further 
incubation with Daudi cells, but again higher levels were 
found in response to the alternative, and particularly alt-1 
and alt-2 DC (Figure 9b). Shifting to the adaptive immu-
nity, CD4+ and CD8+ T cells migrating to SEB-pulsed 
DC were able to secrete IFNγ in an antigen-specific way, 
which was higher upon interaction with alt-1 and alt-2 
DC (Figure 9c).
Figure 4 qPCR evaluation of chemokine gene expression in differently matured DC. The expression levels of chemokine genes in immature DC 
as well as in DC stimulated with gold standard, alt-1, alt-2 and alt-3 maturation cocktails were evaluated by qPCR. Results were first normalised to 
the mean expression of two housekeeping genes (GAPDH and HPRT1) and then toward the gold standard DC. The results are represented as the 
mean ± SE of 9–12 different donors. *p < 0.05, ns p > 0.05 in the Tukey post hoc test.
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Attraction of PBMC derived from cancer patients
“Wash out” supernatants of the differently matured DC 
were also used to determine the attraction of PBMC 
derived from patients with melanoma or renal cell car-
cinoma (RCC) in order to evaluate the behaviour of 
cells from cancer patients before clinical translation. 
As shown in Figure  2a an enhanced migration of cells 
and particularly monocytes was found in response to 
the “wash out” supernatants of alternative DC, which 
is in line with the results obtained using PBMC from 
healthy donors. Phenotypic characterisation of the 
migrated monocytes revealed an enrichment of cells 
with high HLA-DR expression levels (Figure  2b). The 
migrated monocytes displayed also slightly reduced 
expression of CD11b and CD33 (data not shown) sug-
gesting the recruitment of inflammatory cells and not 
of CD33high CD11bhigh HLA-DRlow myeloid derived 
suppressor cells. In addition, comparable and low abso-
lute numbers of CD3+ CD4+ CD25high CD127low Treg 
were attracted by the different supernatants. Despite 
a trend toward enrichment of Treg within the CD4+ T 
cell compartment in response to gold standard and alt-3 
DC supernatants was found, it did not reach statistical 
significance. Moreover, determination of the number of 
Treg within the total migrated population revealed no 
overall enrichment in Treg in response to any DC super-
natant (Figure 2c).
Discussion
Many attempts have been performed in order to improve 
the clinical outcome of cancer patients treated with DC-
based immunotherapy. To this purpose continuous opti-
mization of the protocols for the production of vaccine 
DC are being tested, with changes in the stimuli used 
for the ex vivo differentiation of CD14+ monocytes or 
CD34+ precursor cells as well as for their maturation.
The omic-based technologies now allow not only the 
comparison of these populations by functional assay, 
but also at the transcriptomic and proteomic levels. In 
this way multiple differences between protocols can be 
Figure 5 Evaluation of chemokine production at the protein level in differently matured DC. a “Wash out” supernatants collected 24 h after seeding 
mature DC in the absence of exogenous stimuli were used to evaluate chemokine secretion by sandwich ELISA or flow cytometry based plexing. 
The results are represented as the mean ± SE of 4–7 different donors. b The presence of transmembrane (TM)-CXCL16 on mature DC was evalu-
ated by flow cytometry. The results are shown as mean ± SE of the x-fold increase in MFI over immature DC determined from ten different donors. 
*p < 0.05 in the Tukey post hoc test.
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identified and their impact on the overall functionality of 
the vaccine further evaluated.
In this study we focused our attention on the Fast pro-
tocol for DC differentiation [5], whose shorter ex vivo 
cultivation time might support their clinical translation 
when compared to the 6 day protocol of classical mono-
cyte-derived DC both for reduced costs and decreased 
possibility of contamination of the vaccine during 
handling. Regarding the maturation stimuli, the clinical 
gold standard cytokine cocktail [18] was compared to 
TLR ligand and IFNγ-containing cocktails, namely the 
alt-1 or α-type 1 polarising [7] and the alt-2 [8], that have 
already been characterized at the functional level in a 
previous report [11].
A larger number of genes were differentially expressed 
in response to the two alternative cocktails over 
Figure 6 qPCR evaluation of chemokine gene expression in 24 h “wash out” DC. Mature DC were seeded for 24 h in the absence of exogenous 
stimuli and then collected for mRNA extraction and qPCR evaluation. Results were first normalised to the mean expression of two housekeeping 
genes (GAPDH and HPRT1) and then toward the gold standard DC. The results are represented as the mean ± SE of three different donors. *p < 0.05 
in the Tukey post hoc test.
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immature DC than in response to the gold standard, 
underlining the higher level of differentiation/matura-
tion obtained with such alternative cocktails. The up-
regulation of many genes involved in the interaction with 
innate cells is in line with our previous demonstration of 
the enhanced ability of such DC to stimulate the cytolytic 
and cytokine-secreting ability of NK and γδ T cells [11]. 
Surprisingly, the IL12p35 gene responsible for the forma-
tion of the bioactive IL12p70 involved in their activation 
[11] was not found as significantly regulated by the array 
analysis.
Different members of the chemokine family were 
included among the genes with the strongest levels and 
statistical significance of modulation. Comparison of the 
differently matured DC highlighted an almost opposite 
up-regulation of these members between gold standard 
and alternative DC.
In line with previous studies, stimulation with PGE2 
inhibited the expression of inflammatory chemokines 
[19, 20], while inducing the production of CCL17 and 
CCL22 [21]. Despite the involvement of such chemokines 
in the attraction of Th2 and Treg cells [22], no statistically 
significant enhanced migration of Treg toward superna-
tants from gold standard DC was detected. In addition 
to the high inter-donor variability in the migration assay 
on both healthy DC and patient-derived PBMC, a possi-
ble explanation might be the concomitant expression of 
CCL23 (Figure  8a) that has been proposed to contrast 
Treg recruitment [23].
Another chemokine specifically up-regulated by the 
gold standard DC is CXCL16 that despite present at com-
parable levels in the culture supernatants of all mature 
DC was specifically retained on the surface of gold stand-
ard DC. This might be due to the absence in the matu-
ration cocktail of IFNγ that has been reported to foster 
the shedding of the transmembrane CXCL16 [24]. The 
functional consequences of such specific CXCL16 reten-
tion on gold standard DC is currently under evaluation. 
Indeed, the specific receptor CXCR6/Bonzo is expressed 
by CD45RO+ memory T cells [25] and has been reported 
to play an important role for antigen-specific T cell acti-
vation [26]. Concerning the innate immunity CXCR6 and 
CXCL16 play a key role within the liver, where they are 
involved in the action of NKT cells, either for immuno-
surveillance [27] or suppression [28], and for hapten-spe-
cific memory NK cells [29].
With the exception of CCL17, CCL22 and CXCL16 the 
gold standard DC were poor producers of chemokines 
and indeed in functional assay their “wash out” super-
natants displayed a reduced ability to induce leukocytes 
recruitment. In contrast, the alternative DC did up-reg-
ulate many inflammatory chemokines belonging to both 
the CC and CXC family, resulting in enhanced attrac-
tion of effector cells in vitro. The retained high expres-
sion levels of the encoding mRNA 24 h after the end of 
the maturation suggest that upon in vivo injection the 
DC should still be able to produce chemokine and thus 
facilitate their interaction with effector cells. Whereas 
Figure 7 Expression and functionality of CCR7 by differently matured DC. a Mature DC were evaluated by flow cytometry for the expression of 
CCR7. The x-fold increase in MFI over immature DC is show as mean ± SE of 13 different donors. b The ability of mature DC to migrate toward the 
CCR7 ligands CCL21 was evaluated in a trans-well migration assay. After 3 h incubation at 37°C, DC migrated in the lower chamber were counted by 
flow cytometry. The results of three experiments are represented as mean ± SE upon normalization to the gold standard DC. *p < 0.05 in the Tukey 
post hoc test.
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alt-1 and alt-2 DC displayed few differences, alt-3 DC 
obtained by stimulation with a third alternative cocktail 
[9, 11] presented a slightly different expression pattern. 
As determined by ELISA or multiplexing, alt-3 DC had 
a much lower or even absent secretion of CCL3, CCL4, 
CCL5 as well as of CXCL10 and CXCL11, chemokines 
for which additional “co-stimulatory” activity on immune 
cells other than chemoattraction have been reported. 
These chemokines can induce changes in cell adhesive-
ness and promote the formation and the stability of the 
immunological synapse between DC and T cells [30, 31]. 
Moreover, they have been involved in the promotion of 
the cytotoxic activity [32–37] and proliferation of NK and 
T cells [38, 39] and to provide co-stimulatory signals for 
T cells [40]. Since for the three CXCR3 ligands CXCL9 
CXCL10 and CXCL11 different and sometimes opposing 
function have been reported depending on the particu-
lar infection or pathology investigated [41], the different 
pattern of chemokine secretion among the alternative 
DC might promote their individual implementation in 
specific vaccine formulations depending on the particu-
lar clinical setting.
Another difference among the various alternative DC 
was the increased attraction of monocytes by alt-3 when 
compared to alt-1 and even more to alt-2 DC, an abil-
ity that could be linked to their secretion of CCL2 and 
CCL8. In cancer patients, the enhanced attraction of 
monocytes was not associated with the phenotype of 
myeloid derived suppressor cells that could potentially 
down regulate the vaccine functionality, since there was 
an enrichment of HLA-DRhigh migrating monocytes. 
In light of the demonstration in various murine models 
that vaccination with DC can also relay on endogenous 
APC for their immunological functions [42–45], it will be 
important to evaluate the functional capability of those 
cancer-associated myeloid cells in order to confirm a 
possible role in fostering vaccine efficacy. Recently, CCL2 
has also been involved in the recruitment of murine γδ T 
cells as well as human Vδ1+, but not of Vδ2+ cells [46]. 
Due to the low amount of Vδ1+ T cells in the peripheral 
Figure 8 Determination of chemokines involved in monocyte chemoattraction. a The expression of different members of the monocyte chemoat-
tractant protein family was evaluated by qPCR. Results are first normalised to the mean expression of two housekeeping genes (GAPDH and HPRT1) 
and then toward gold standard DC. The relative expression of nine different donor is represented as mean ± SE. *p < 0.05, ns p > 0.05 in the Tukey 
post hoc test. b The CCL2 and CCL8 concentration of “wash out” supernatants from mature DC seeded in the absence of exogenous stimuli for 24 h 
were determined by sandwich ELISA. The results are represented as mean ± SE of 8–12 different donors. *p < 0.05, ns p > 0.05 in the Tukey post hoc 
test.
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blood, an enhanced attraction of this population by 
alt-3 DC could not be detected. However, this possible 
interaction might be worth to investigate since different 
tumor types are infiltrated by Vδ1+ T cells [47, 48] and 
anti-tumor activity against solid as well as hematologic 
malignancies have been reported both in vitro [49] and 
in xenograft transplantation models [50, 51], resulting in 
the establishment of expansion protocol for clinical ther-
apy [52].
Opposite to the enhanced chemo-attracting capac-
ity of the alternative DC are their reduced migratory 
properties. Indeed, despite an upregulation of CCR7 
even higher than gold standard DC, alternative DC dis-
played a reduced migration in vitro toward its ligand 
CCL21 and would then have poor migration to the 
lymph node upon subcutaneous or intradermal injec-
tion into cancer patients. Two possible approaches can 
be used to overcome this problem. On one side, further 
in vitro manipulation can be performed to enhance the 
receptor functionality. Pretreatment of murine DC with 
recombinant CCL17 or CCL22 has been demonstrated to 
enhance their responsiveness to CCR7 as well as CXCR4 
ligands without affecting the receptor expression nor 
being dependent on CCR4 expression [53]. Similarly, 
addition of LTC4 to various maturation stimuli was able 
to enhance CCR7 responsiveness to its ligands with a 
similar potency to PGE2 but without impairing the DC 
capability to secrete functional IL12 [54]. Otherwise the 
in vivo injection route can be modified shifting from 
the subcutaneous or intradermal route to the usage of 
intralymphatic cannulation or direct intranodal injec-
tion. Indeed, despite some clinical trials directly com-
paring the different routes of injection have highlighted 
better results with the former two sites, they were also 
performed with a “not yet optimised” DC formulation, in 
which the in vivo migration step would still be required 
to further select the most mature DC within the vaccine 
[55–58]. Production of DC vaccine with new formula-
tions like the proposed alternative cocktails that lead to 
a highly homogeneous and mature DC population would 
not need further in vivo selection and could thus be 
directly delivered into the lymph nodes to attract effec-
tor cells and induce their functional activation bypassing 
their poor migratory capacity.
Figure 9 Functional activation of lymphocytes migrated to alternatively matured DC. a, b 5 × 105 mature DC were seeded in 12 well plate for 4 h, 
after which 3 × 106 autologous PBMC were added above a 3 μm insert. After 18 h incubation the cells that had migrated into the bottom chamber 
were taken and either immediately evaluated for IFNγ secretion (a) or incubated for 4 h in the presence of Daudi cells and evaluated for CD107a 
degranulation (b). c 5 × 105 mature DC were pulsed with SEB for 30 min at 37°C, washed and then seeded in 12 well plate for 4 h, after which 
3 × 106 autologous PBMC were added above a 3 μm trans-well insert. After 4 h incubation the cells in the bottom chamber were taken and evalu-
ated for IFNγ secretion. Shown is one representative experiment out of two (c) or three (a, b) with similar results.
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Overall, this study demonstrated a higher functional-
ity of alt-1 and alt-2 DC over gold standard DC. Despite 
sharing many differentially expressed genes, the two 
alternative DC displayed also some differences that need 
to be evaluated in order to determine the consequence 
on the activity of the DC vaccine. Furthermore, a reduced 
chemoattractant property of gold standard DC was iden-
tified, which might represent a possible cause in addition 
to the missing IL12p70 secretion for their poor clinical 
efficacy.
Conclusions
In this study we demonstrated that vaccine DC stimu-
lated with the gold standard maturation cocktails dis-
play a limited production of chemokines resulting in a 
reduced ability to recruit effector cells in their proxim-
ity. In contrast, stimulation of DC with cocktails based 
on IFNγ and different TLR ligands resulted in enhanced 
attraction and following activation of effector cells from 
both the innate and the adaptive immune response. 
Monocytes were also highly attracted by the alternative 
DC and the high levels of HLA-DR expression in mono-
cytes attracted within cancer patients suggest that they 
are not suppressive MDSC but could be functionally 
active antigen presenting cells able to further boost the 
effect of the vaccine DC.
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